drugset / Trial / NCT07354477

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

NCT07354477

Phase 2 Recruiting 14 enrolled Qlaris Bio, Inc.
NaSequentialOpen-labelTreatment

Summary

Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG

Timeline

Start
2026-02-20
Primary completion
2026-09
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject QLS-111 Unknown 0.015 %
Subject QLS-111 Unknown 0.075 %